Company intelligence / Profile preview

Xylos

Langhorne, Pennsylvania, United Statesxylos.com ↗

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Xylos has developed a unique cellulose-based biomaterial that mimics natural tissue. Its lead product—a cellulose matrix wound dressing—has demonstrated effectiveness in autolytic debridement and healing of chronic venous ulcers in clinical trials. The company has received FDA 510(k) clearance for its initial wound care line and continues to develop new surgical implant products.

Therapeutic areas: DermatologyRheumatology
Modalities: Device (biomaterial wound dressings and surgical implants)
Industry: Consumable Medical Devices

Partnerships

Some university collaborations mentioned; specifics not listed.

Beyond the preview

Go deeper on Xylos.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xylos.

Explore the full profile